Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with LDL-C of 130 through 190 mg/dL and Triglycerides less than or equal to 500 mg/dL~* Patient willing to be on a low-cholesterol diet~Exclusion Criteria:~* Pregnant or lactating women or intending to become pregnant~* Patient with sensitivity or intolerance to ezetimibe, simvastatin, or ezetimibe/simvastatin combination tablet~* Patient with sensitivity or intolerance ro niacin, any component or niacin extended release or aspirin~* Patient for whom discontinuation of existing lipid-lowering therapy treatment poses an unacceptable risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Part 1 - Arm 1 (Type: ACTIVE_COMPARATOR): ezetimibe/simvastatin combination tablet + niacin (ER)
- Part 1 -Arm 2 (Type: ACTIVE_COMPARATOR): ezetimibe/simvastatin
- Part 1 - Arm 3 (Type: ACTIVE_COMPARATOR): Niacin (ER)
- Part 2 - Arm 1 (Type: ACTIVE_COMPARATOR): ezetimibe/simvastatin combination tablet + niacin (ER)
- Part 2 - Arm 2 (Type: PLACEBO_COMPARATOR): ezetimibe/simvastatin combination tablet + niacin (Pbo)

Based on this trial design, predict the completion outcome and termination type (if applicable).